Briefing
- CVS Caremark is reinstating coverage of Eli Lilly's injectable weight-loss drug Zepbound and adding Lilly's obesity pill to its drug plans, reversing an earlier exclusion that triggered patient backlash.
- Lilly slashed the price of Zepbound, a concession that unblocked the coverage decision at the largest US pharmacy benefit manager by covered lives.
- The reinstatement also extends to Foundayo, broadening the range of Lilly obesity treatments now accessible to CVS plan members.
- Lilly shares moved toward a record high on the news, according to The Wall Street Journal, reflecting market expectations that broader PBM coverage will materially lift Zepbound prescription volumes.
- The key forward read is whether competing PBMs, and health insurers that follow CVS formulary decisions, will accelerate their own Zepbound coverage reviews given the price concession Lilly has now demonstrated it will make.
Analysis
- Competing PBMs and insurers that shadow CVS formulary decisions now face pricing pressure to match Lilly's concession, compressing GLP-1 net pricing across the PBM channel within 6-12 months. Lilly has demonstrated willingness to cut list price to secure formulary access; Express Scripts and OptumRx can extract the same concession using CVS as a reference price. The resulting net price erosion limits the revenue upside LLY captures from volume gains, creating a margin squeeze that the share move toward record highs may not fully discount.
- Novo Nordisk's Wegovy and Ozempic face formulary share erosion at CVS plan members now that Zepbound is reinstated, intensifying a head-to-head commercial competition that shifts pricing power from manufacturers to PBMs. CVS previously excluded Zepbound in a move that concentrated volume on Novo's drugs; reinstatement reverses that channel advantage. With Lilly having shown it will price to access, Novo faces the same PBM leverage in its next formulary renegotiation cycle, compressing net GLP-1 pricing sector-wide.
Historical Context
- 2023
CVS Caremark excluded Humira biosimilars from its 2023 formulary in exchange for deeper AbbVie rebates, demonstrating that PBMs extract price concessions by credibly threatening exclusion. The Zepbound reinstatement follows identical mechanics: exclusion was the lever, a price cut was the concession, and coverage was restored.
- 2016–2018
PBM-driven net price compression in the insulin market saw list prices held or raised while net prices to PBMs fell sharply via rebates, collapsing manufacturer revenue per unit even as volume grew. GLP-1 drugs are now entering a structurally similar PBM rebate dynamic as coverage scales and competition between Lilly and Novo intensifies.
Connected Events
Further reading
See Indexa more often on Google
Mark Indexa as a preferred source — your Top Stories will surface more Indexa coverage.
